$TLSA News
Last published 3d ago
- 3d agoTLSATiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal ForalumabGlobeNewswireBOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its
- 3d agoTLSATiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal ForalumabGlobeNewswireBOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today provided additional context on the positive topline results from its Phase 2a INFORM-MS trial, build ...
- 3d agoTLSAINTRANASAL FORALUMAB INFORM-MS KOL WEBCAST - TIZIANA LIFE SCIENCES LTDEarnings Call TranscriptsWell, welcome, everybody. Today, we're here. It's a lovely day, November 9. We're here to talk about our Phase 2 results in the INFORM-MS trial, which was a Phase 2 placebo-controlled double-blind trial of intranasal fer
- 4d agoTLSATiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL WebcastGlobeNewswireBOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its
- 1w agoTLSATiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline ResultsGlobeNewswireTrial met primary endpoint with a statistically significant reduction in microglial activation on TSPO PET (p=0.0168)Intranasal foralumab is the first non-invasive anti-CD3 therapy that has shown a favorable safety and
- 1w agoTLSATiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisGlobeNewswireTrial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as compared to placebo
- 3w agoTLSATiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in TorontoGlobeNewswireBOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its
- 4w agoTLSATiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s DiseaseGlobeNewswireBOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its
- 1mo agoTLSATiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal ForalumabGlobeNewswireBOSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its
- 1mo agoTLSATiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research CenterGlobeNewswireBOSTON, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its
- 2mo agoTLSATiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026GlobeNewswireBOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its
- 3mo agoTLSATiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerGlobeNewswireBOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its
- 3mo agoTLSATiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal ForalumabGlobeNewswireBOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal
- 3mo agoTLSATiziana Life Sciences Announces Purchase of Shares by Executive ChairmanGlobeNewswireBOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its
- 4mo agoTLSATiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS TrialGlobeNewswireTop line data readout expected in late Q3/early Q4INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple
- 5mo agoTLSATiziana Life Sciences Announces Purchase of Shares by Executive ChairmanGlobeNewswireBOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 5mo agoTLSATiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New YorkGlobeNewswireBOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody,
- 5mo agoTLSATiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis TrialGlobeNewswireBOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody,
- 5mo agoTLSATiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisGlobeNewswireFavourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a
- 6mo agoTLSATiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal ForalumabGlobeNewswireBOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody,
- 7mo agoTLSATiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive FunctionGlobeNewswireBOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal
- 7mo agoTLSATiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson CongressGlobeNewswireBOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal
- 7mo agoTLSATiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with AgingGlobeNewswireBOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal
- 8mo agoTLSATiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRAGlobeNewswireBOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal
- 9mo agoTLSATiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal ForalumabGlobeNewswireBOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody,
- 10mo agoTLSATiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary SharesGlobeNewswireBOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal
- 10mo agoTLSATiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 MillionGlobeNewswireBOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody,
- 10mo agoTLSATiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San FranciscoGlobeNewswireBOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal
- 10mo agoTLSATiziana Files Annual Safety Report for Intranasal Foralumab with FDAGlobeNewswireTiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi's tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec. 29, 2025 (GLOBE
- 10mo agoTLSATiziana Life Sciences Announces Acquisition of Shares by Executive ChairmanGlobeNewswireBOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 11mo agoTLSATiziana Life Sciences to Ring the Closing Bell at NasdaqGlobeNewswireBOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 11mo agoTLSATiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical TrialGlobeNewswireFirst Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer's Patients Treated with Anti-Amyloid Therapies BOSTON,
- 11mo agoTLSATiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerGlobeNewswireBOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 11mo agoTLSATiziana Life Sciences Announces Withdrawal of Proposed Public OfferingGlobeNewswireBOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 11mo agoTLSATiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's TrialGlobeNewswireFirst Patient Expected to be Dosed Next Week with Intranasal ForalumabPET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi® (Lecanemab) Anti-Amyloid Therapy BOSTON, Dec. 12,
- 11mo agoTLSATiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed CompanyGlobeNewswireBOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it
- 11mo agoTLSATiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch ProgramGlobeNewswireBOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its
- 1y agoTLSATiziana Life Sciences to Present at Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 1y agoAQSTTLSAAquestive Therapeutics Announces Leadership Expansion to Support GrowthGlobeNewswireChanges strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company's ongoing development initiatives Matthew Davis, M.D.,
- 1y agoTLSATiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation TherapyGlobeNewswireBOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 1y agoTLSATiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi ArabiaGlobeNewswireBOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 1y agoTLSATiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal AntibodyGlobeNewswireBOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
- 1y agoTLSATiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS CongressGlobeNewswireBOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 1y agoTLSADepartment of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord InjuryGlobeNewswireBOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 1y agoTLSATiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerGlobeNewswireBOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 1y agoTLSATiziana Life Sciences Announces Purchase of Shares by ChairmanGlobeNewswireBOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 1y agoTLSATiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System AtrophyGlobeNewswireBOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 1y agoTLSAFDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System AtrophyGlobeNewswireNEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 1y agoTLSATiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's PatientGlobeNewswireNEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development
- 1y agoTLSATiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis CenterGlobeNewswireNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development